Contact Us

Drug Coated Stents
*    Denotes required field.

   * First Name 

   * Last Name 

   * Email 

Phone 

Cell Phone 

Street Address 

Zip Code 

City 

State 

Which drug-coated stent was implanted?

Date the device was implanted:

Is the device still implanted?

What medical condition prompted the use of the device?

Did you develop blood clotting?

Please describe any problems or injuries caused by the product:

For verification purposes, please answer the below question:
+
=

No Yes, I agree to the Parker Waichman LLP disclaimers. Click here to review.

Yes, I would like to receive the Parker Waichman LLP monthly newsletter, InjuryAlert.

please do not fill out the field below.


Data: Drug-coated stents carry clot risk

Oct 24, 2006 | UPI

Data presented at a Washington medical conference revealed that drug-coated stents create a higher risk of blood clots than traditional metal stents.

The data, presented at the Transcatheter Cardiovascular Therapeutics meeting, revealed that the drug-coated stents, manufactured by Boston Scientific Corp. and Johnson & Johnson, carry a statistically significant higher risk of blood clots that could lead to major heart attacks, The Wall Street Journal reported Tuesday.

The data were taken from 1,800 patients implanted with Boston Scientific Corp.'s Taxus stent and 3,500 patients implanted with Johnson & Johnson's Cypher stent. Analysis of the data revealed that the Taxus stent caused a 0.4-percent risk of blood clot, while the Cypher stent caused a 0.6-percent risk. While the percentages are small, experts said they are statistically significant. The experts said stent blood clots have a 70-percent chance of causing major heart attacks and deaths.

A Johnson & Johnson spokesman said the numbers "are subject to interpretation by a number of methodologies, some of which may yield significant differences at certain time points."


Other articles
Parker Waichman Accolades And Reviews Best Lawyers Find Us On Avvo